Drug intelligence / Profile preview

HS-130 + viagenpumatucel-L

Development stage: Unknown
Lead developer: Heat Biologics
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

**HS-130 + viagenpumatucel-L** is an experimental combination immunotherapy comprised of two allogeneic cellular vaccines administered intradermally for the treatment of advanced solid tumors refractory to standard care. HS-130 is a human cell line engineered to express OX40L-Ig, designed to provide T cell co-stimulation, while HS-110 (viagenpumatucel-L) is derived from a human lung adenocarcinoma cell line (AD100) expressing HLA-A1 and gp96-Ig, a fusion protein that acts as an antigen-presenting cell (APC) adjuvant and delivers a repertoire of cancer/testis antigens for immunization, targeting CD8+ cytotoxic T cells. The combination aims to induce a robust, antigen-specific, cell-mediated immune response against tumor cells by co-administering costimulatory and antigen-presenting signals[3][5].

Other names: HS-130/HS-110

Targets

CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on HS-130 + viagenpumatucel-L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-130 + viagenpumatucel-L.

Explore the full profile